Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCGONASDAQ:EUDANASDAQ:OPGNNASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCGODocGo$1.38+1.1%$2.10$1.23▼$5.68$140.23M1.14799,728 shs133,179 shsEUDAEUDA Health$3.54+2.8%$3.80$2.21▼$6.30$131.37M-0.0582,190 shs361 shsOPGNOpGen$4.70-1.3%$4.42$0.53▼$5.25$47.32M-1.7110,156 shs1,760 shsXGNExagen$7.03+0.7%$5.31$1.71▼$7.20$149.65M1.5190,656 shs96,717 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCGODocGo0.00%+1.49%-40.35%-55.99%-55.26%EUDAEUDA Health-4.19%-6.77%-9.97%-10.68%+29.43%OPGNOpGen+1.28%-2.46%-4.61%+433.33%+34.46%XGNExagen+4.18%+15.75%+1.45%+101.73%+265.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCGODocGo3.4892 of 5 stars3.33.00.00.03.42.51.9EUDAEUDA Health0.5976 of 5 stars0.03.00.00.02.90.00.6OPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/AXGNExagen3.7465 of 5 stars2.53.00.04.52.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCGODocGo 2.50Moderate Buy$3.56158.91% UpsideEUDAEUDA Health 4.00Strong BuyN/AN/AOPGNOpGen 0.00N/AN/AN/AXGNExagen 3.00Buy$7.506.75% UpsideCurrent Analyst Ratings BreakdownLatest OPGN, XGN, EUDA, and DCGO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025XGNExagenUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.005/13/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/12/2025DCGODocGoCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$5.00 ➝ $1.455/9/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.005/9/2025DCGODocGoBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/7/2025XGNExagenBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/8/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/12/2025XGNExagenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2025DCGODocGoStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.50 ➝ $5.502/28/2025DCGODocGoDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$5.00 ➝ $2.85(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCGODocGo$520.50M0.27$0.06 per share23.62$2.93 per share0.47EUDAEUDA Health$4.01M32.75N/AN/A($0.30) per share-11.79OPGNOpGen$2.67M17.70N/AN/A($11.55) per share-0.41XGNExagen$56.72M2.64N/AN/A$1.33 per share5.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCGODocGo$6.86M-$0.024.9117.1914.164.35%8.90%5.72%8/6/2025 (Estimated)EUDAEUDA Health-$10.04MN/A0.00N/AN/AN/AN/AN/A5/30/2025 (Estimated)OPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%6/2/2025 (Estimated)XGNExagen-$23.69M-$0.84N/AN/AN/A-30.36%-92.58%-33.74%8/4/2025 (Estimated)Latest OPGN, XGN, EUDA, and DCGO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025XGNExagen-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million5/8/2025Q1 2025DCGODocGo-$0.01-$0.09-$0.08-$0.09$104.25 million$96.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCGODocGoN/AN/AN/AN/AN/AEUDAEUDA HealthN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCGODocGoN/A2.192.19EUDAEUDA HealthN/A0.13N/AOPGNOpGenN/A5.455.45XGNExagen1.544.054.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCGODocGo56.44%EUDAEUDA Health4.35%OPGNOpGen2.68%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipDCGODocGo2.70%EUDAEUDA HealthN/AOPGNOpGen43.80%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCGODocGo2,920101.98 million99.30 millionOptionableEUDAEUDA Health237.15 millionN/ANot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionableXGNExagen22021.30 million13.03 millionOptionableOPGN, XGN, EUDA, and DCGO HeadlinesRecent News About These CompaniesToronto Dominion Bank Acquires New Holdings in Exagen Inc. (NASDAQ:XGN)May 25, 2025 | marketbeat.comStonepine Capital Management LLC Reduces Stock Holdings in Exagen Inc. (NASDAQ:XGN)May 20, 2025 | marketbeat.comResearch Analysts Issue Forecasts for Exagen FY2025 EarningsMay 20, 2025 | marketbeat.comFY2025 EPS Estimates for Exagen Reduced by Cantor FitzgeraldMay 20, 2025 | americanbankingnews.comCanaccord Genuity Group Issues Positive Forecast for Exagen (NASDAQ:XGN) Stock PriceMay 15, 2025 | marketbeat.comDriehaus Capital Management LLC Takes Position in Exagen Inc. (NASDAQ:XGN)May 12, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Call TranscriptMay 11, 2025 | insidermonkey.comWilliam Blair Has Pessimistic Outlook of Exagen Q2 EarningsMay 10, 2025 | marketbeat.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional SharesMay 9, 2025 | finance.yahoo.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional SharesMay 9, 2025 | globenewswire.comWilliam Blair Forecasts Exagen's Q1 Earnings (NASDAQ:XGN)May 9, 2025 | marketbeat.comExagen Inc. Prices Public Offering of Common StockMay 8, 2025 | globenewswire.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comExagen Inc. Announces Proposed Public Offering of Common StockMay 7, 2025 | globenewswire.comExagen (NASDAQ:XGN) Issues Quarterly Earnings ResultsMay 7, 2025 | marketbeat.comExagen (XGN) Expected to Announce Earnings on MondayMay 7, 2025 | marketbeat.comEarnings call transcript: Exagen Inc. Q1 2025 revenue beats forecasts, stock dipsMay 6, 2025 | uk.investing.comExagen Inc. Reports Record Revenue Amid Strategic GrowthMay 6, 2025 | tipranks.comExagen Inc. Earnings Call Highlights Record GrowthMay 5, 2025 | tipranks.comExagen Inc. (XGN) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPGN, XGN, EUDA, and DCGO Company DescriptionsDocGo NASDAQ:DCGO$1.38 +0.02 (+1.10%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.EUDA Health NASDAQ:EUDA$3.54 +0.10 (+2.79%) As of 11:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.OpGen NASDAQ:OPGN$4.70 -0.06 (-1.26%) As of 10:27 AM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Exagen NASDAQ:XGN$7.03 +0.05 (+0.66%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
